Results 221 to 230 of about 33,041 (261)

Immunological evaluation of predicted linear B‐cell epitopes of human CD20 antigen

Biotechnology and Applied Biochemistry, 2012
AbstractThe importance of B‐lymphocyte‐restricted differentiation antigen Bp35 (CD20) as a target for immunotherapeutic depletion of B cells is irrefutable. Several anti‐human CD20 (anti‐hCD20) monoclonal antibodies are expressed at different stages of development.
Mahdi Habibi, Anbouhi, Mohsen, Abolhassani, Saeid, Bouzari, Hossein, Khanahmad, Mohammad Reza, Aghasadeghi, Armin, Madadkar-Sobhani, Amir, Amanzadeh, Mahdi, Behdani, Mohammad Ali, Shokrgozar   +8 more
openaire   +2 more sources

Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen

Cancer Biotherapy and Radiopharmaceuticals, 2015
The rapid expansion of immunotherapeutic approaches for treatment of various diseases, including cancers, has been greatly facilitated by the invention of new generation of antibodies. Clinical studies have indicated that anti-CD20 mAb-based therapies represent an effective treatment for various diseases with overexpression of CD20
Mahdi, Habibi-Anbouhi, Kayhan, Azadmanesh, Mahdi, Behdani, Ensiyeh, Hajizadeh-Saffar, Rouhollah, Vahabpour, Mohammad Ali, Shokrgozar   +5 more
openaire   +2 more sources

Characterization of Self-Assembled Monolayers of Peptide Mimotopes of CD20 Antigen and Their Binding with Rituximab

Langmuir, 2015
CD20, expressed in greater than 90% of B-lymphocytic lymphomas, is a target for antibody therapy. Rituximab is a chimeric therapeutic monoclonal antibody (mAb) against the protein CD20, allowing it to destroy B cells and to treat lymphoma, leukemia, transplant rejection, and autoimmune disorder.
Norman, Leo, Yuqin, Shang, Jing-jiang, Yu, Xiangqun, Zeng   +3 more
openaire   +2 more sources

The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders

Expert Opinion on Biological Therapy, 2011
Immunotherapy using an antibody (rituximab) targeting CD20 antigen in combination with chemotherapy has been recently associated with significantly improved response rate and survival in patients with various types of CD20-positive B-cell lymphoproliferative disorders. This treatment may induce the disappearance of CD20 surface expression on neoplastic
Musto P, D'Auria F
openaire   +2 more sources

In Silico Analysis for Determination and Validation of Human CD20 Antigen 3D Structure

International Journal of Peptide Research and Therapeutics, 2017
CD20 has been known as an attractive therapeutic target for refractory diseases such as B-cell chronic lymphocytic leukemia, rheumatoid arthritis and multiple sclerosis. Determining the 3D structure of the CD20 antigen could help to achieve a better deduction of its functions and its interactions with ligands.
Zahra Payandeh, Masoumeh Rajabibazl, Yousef Mortazavi, Azam Rahimpour   +3 more
openaire   +1 more source

Effect of interferon-α on CD20 antigen expression of B–cell chronic lymphocytic leukemia

Cytokines, Cellular & Molecular Therapy, 2000
Chimeric CD20 monoclonal antibody as alternative therapy in relapsed low-grade non-Hodgkin's lymphoma (NHL) has produced responses in nearly 50% of patients. Augmenting CD20 expression on tumor cells and/or inducing its expression may increase the cell kill and effectiveness of antibody therapy. Peripheral blood lymphocytes from 19 patients with B-cell
S, Sivaraman, P, Venugopal, R, Ranganathan, C G, Deshpande, X, Huang, A, Jajeh, S A, Gregory, T, O'Brien, H D, Preisler   +8 more
openaire   +2 more sources

GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes

Leukemia Research, 2005
CD20 antigen expression in B-chronic lymphocytic leukemia (B-CLL) is at significantly lower levels than in non-Hodgkins lymphoma, which may affect the degree of anti-CD20 antibody binding. Low density of CD20 expression on malignant cells may explain the lower response rates to anti-CD20 monoclonal antibody, observed in B-CLL.
Yagci, M, Akar, I, Sucak, GT, Haznedar, R   +3 more
openaire   +3 more sources

Construction and Characterizationc of a Camelized, Human, VH-based Peptide Vaccine Against CD20 Antigen

Immunotherapy, 2013
The purpose of this study was to construct and characterize a camelized, human, heavy-chain variable (VH) fragment-based peptide vaccine against CD20 antigen.Camelized, human VH with improved solubility and stability was used as a vaccine scaffold. A CD20 B-cell epitope was introduced into the complementarity determining region 3 of the engineered VH ...
Jianbin, Liu, Yanguo, Tan, Ranxing, Zhang   +2 more
openaire   +2 more sources

Improved antigen binding by a CD20-specific single-chain antibody fragment with a mutation in CDRH1

Molecular Immunology, 2006
We have prepared single-chain immunoglobulin Fv fragments from the CD20-specific hybridoma HB13d. One scFv clone demonstrated strong binding to a CD20-derived peptide by ELISA and to CD20-positive cells by flow cytometry, a second had reduced binding, and a third clone did not bind the target antigen.
Adamson, P., Millard, D., Hohmann, A., Mavrangelos, C., Macardle, P., Pilkington, G., Mulhern, T., Tedder, T., Zola, H., Nicholson, I.   +9 more
openaire   +3 more sources

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.

Clinical cancer research : an official journal of the American Association for Cancer Research, 1999
Rituximab is a chimeric antibody with human gamma-1 and kappa constant regions and murine variable regions. It recognizes the CD20 antigen, a pan B-cell marker. Therapeutic trials in patients with B-cell non-Hodgkin's lymphoma (NHL) have shown significant efficacy with a primary response rate of 50%, and a secondary response rate of 44% after repeat ...
T A, Davis, D K, Czerwinski, R, Levy
openaire   +1 more source